Saturday 17 October 2026 Export PHR’s income statement to Excel — free account

Phreesia, Inc.

PHR Healthcare Health Information Services

Phreesia, Inc.’s revenue for fiscal 2026 (year ended January 2026) was $480.6 million, up 14.5% from fiscal 2025. In the quarter to July 2026, revenue grew 10.4%, EPS grew 200.0%, free cash flow grew 43.5% and total debt rose 3,191.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

10.94 0.10 −0.91%

Follow PHR

Alert me

Market cap: $685.3M
P/E: 64.4×
Fwd P/E: 23.5×
Dividend yield: —
F-score: 5/9
Altman Z: 0.65
Beneish M: −2.15
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 28.77

Total sells 1.96

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	—	—	—	—	—
Sell	—	2	14	—	3	5	1	1	3	—	1	—

Insider Ownership 8.19%

Capital & Financial Ratios $m

Market Cap 685.26

Revenue 507.79

Net Income 10.45

Free Cash Flow 67.52

Net Debt 77.69

Current Ratio 1.76

Debt/Equity 0.41

P/E ratio 64.35

Fwd P/E 23.50

P/S ratio 1.33

P/B ratio 1.82

Past 5Y EPS Growth —

This Y EPS Growth 647.73%

Next Y EPS Growth 117.99%

Next Y revenue growth 7.33%

Next 5Y EPS Growth 165.29%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 5.90%

10-year low 10-year high

P/B against its own 10 years 8.71%

10-year low 10-year high

EV/Sales against its own 10 years 8.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2016	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	88	84	74	73
Receivables	65	74	155	134
Inventory	—	—	—	—
Other	28	29	33	27
	196	203	280	254

	2024	2025	2026	Q'26
Payables	8	6	11	12
ST’ Debt	—	—	38	30
Other	34	29	34	27
	110	114	183	144

Compound Annual Growth %

	10y	5y	3y
Sales	—	26.45%	19.60%
Cash Flow	—	93.71%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	5.07%	5.42%

Revenue $m

	Apr	Jul	Oct	Jan	Year
’26	131	129	—	—	—
’26	116	117	120	127	481
’25	101	102	107	110	420
’24	84	86	92	95	356
’23	63	68	73	77	281
’22	48	51	56	58	213
’21	33	35	38	42	149

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Apr	Jul	Oct	Jan	Year
’26	24	18	—	—	—
’26	15	15	15	34	79
’25	(1)	11	6	16	32
’24	(14)	(9)	(6)	(3)	(32)
’23	(34)	(20)	(21)	(16)	(90)
’22	(5)	(7)	(25)	(38)	(75)
’21	2	(2)	(1)	4	3

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Apr	Jul	Oct	Jan	Year
’26	16	14	—	—	—
’26	7	10	9	29	54
’25	(6)	4	2	9	8
’24	(20)	(15)	(12)	(11)	(57)
’23	(41)	(26)	(27)	(22)	(116)
’22	(12)	(10)	(39)	(44)	(106)
’21	(1)	(7)	(4)	(3)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Apr	Jul	Oct	Jan	Year
’26	0.05	0.03	—	—	—
’26	(0.07)	0.01	0.07	0.02	0.04
’25	(0.35)	(0.31)	(0.25)	(0.11)	(1.02)
’24	(0.70)	(0.68)	(0.58)	(0.56)	(2.51)
’23	(0.99)	(0.89)	(0.76)	(0.72)	(3.36)
’22	(0.24)	(0.48)	(0.71)	(0.90)	(2.37)
’21	(0.16)	(0.17)	(0.17)	(0.18)	(0.69)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	22.05	16.01	38.91	13.19	12.05	17.07	15.41	7.77	Analyst estimates 2027–2029 Powerpack
	High	—	—	31.00	59.67	81.59	43.47	40.00	29.16	32.76	17.60
People
People	Employees	—	—	436	532	827	1,701	1,546	1,438	2,082	1,789
	Revenue/emp, $m	—	0.00	0.23	0.23	0.18	0.13	0.18	0.25	0.20	0.27
Income, $m
Income, $m	Revenue	—	80	100	125	149	213	281	356	420	481
	Gross margin, %	—	62.71	62.96	64.16	64.77	61.83	61.10	65.19	67.86	67.93
	EBT	—	(18)	(15)	(22)	(27)	(118)	(176)	(135)	(56)	(9)
	EBT margin, %	—	(22.79)	(15.08)	(17.69)	(18.32)	(55.33)	(62.53)	(37.99)	(13.29)	(1.86)
	Net income	—	(18)	(15)	(20)	(27)	(118)	(176)	(137)	(59)	2
	Depreciation	—	12	14	16	18	24	27	31	30	35
Per share, $
Per share, $	Revenue	—	51.87	54.14	6.15	3.76	4.27	5.36	6.53	7.29	8.05
	Earnings	—	(11.82)	(8.16)	(4.50)	(0.69)	(2.37)	(3.36)	(2.51)	(1.02)	0.04
	Cash flow	—	(7.24)	(1.15)	0.04	0.07	(1.50)	(1.72)	(0.59)	0.56	1.32
	Capex	—	(7.77)	(5.33)	(0.61)	(0.47)	(0.62)	(0.50)	(0.46)	(0.42)	(0.41)
	Free cash flow	—	(15.01)	(6.48)	(0.57)	(0.40)	(2.11)	(2.22)	(1.05)	0.14	0.91
	Book value	—	0.00	(2.43)	5.02	6.66	8.36	5.49	4.61	4.60	5.64
	Shares, m	—	2	2	20	40	50	52	55	58	60
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	440.33
	P/S	—	0.00	0.00	5.04	17.74	7.30	7.00	3.90	3.90	1.64
	P/B	—	0.00	0.00	6.18	10.02	3.73	6.83	5.53	6.19	2.34
	EV/Sales	—	0.00	0.00	4.51	16.35	5.89	6.40	3.69	3.74	1.85
	EV/FCF	—	(6.27)	(6.27)	(48.97)	(155.00)	(11.91)	(15.46)	(22.89)	189.37	16.37
Cash, $m
Cash, $m	Operating cash flow	—	(11)	(2)	1	3	(75)	(90)	(32)	32	79
	Capex	—	(12)	(10)	(12)	(19)	(31)	(26)	(25)	(24)	(24)
	Free cash flow	—	(23)	(12)	(11)	(16)	(106)	(116)	(57)	8	54
Balance, $m
Balance, $m	Working capital	—	9	5	96	217	318	183	86	89	97
	Total debt	—	157	30	24	12	15	9	5	8	176
	Net debt	—	146	29	(66)	(206)	(299)	(168)	(82)	(76)	102
	Shareholders’ equity	—	—	(4)	102	263	417	288	251	265	337
Returns, %
Returns, %	ROA	—	(65.59)	(152.75)	(83.87)	(11.24)	(28.78)	(40.75)	(36.98)	(15.43)	0.44
	ROIC	—	(6.22)	(24.33)	(27.00)	(28.17)	(61.88)	(91.98)	(50.37)	(19.24)	(0.94)
	ROE	—	20.16	23.91	167.58	(14.95)	(34.72)	(49.96)	(50.77)	(22.67)	0.77

Negative figures in brackets.

All 10 years →

Fiscal years to Jan 2026 · latest quarter Jul 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OMDA Omada Health, Inc.	$1.1B	252×	143×	+43.12% (above 0%: growing)	n/m	+45.71% (above 0%: growing)	72.62%	4.04%	Compare
TDOC Teladoc Health, Inc.	$1.1B	— (loss-making)	— (loss-making)	−3.95% (below 0%: shrinking)	n/m	−27.07% (below 0%: shrinking)	68.56%	(6.11%)	Compare
HSTM HealthStream, Inc.	$1.0B	46.0×	34.4×	+12.55% (above 0%: growing)	+27.78% (above 0%: growing)	+362.71% (above 0%: growing)	65.35%	9.94%	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)	Compare
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)	Compare
WEAV Weave Communications, Inc.	$594.5M	— (loss-making)	— (loss-making)	+15.52% (above 0%: growing)	n/m	+94.33% (above 0%: growing)	72.03%	(6.49%)	Compare
EVH Evolent Health, Inc	$550.6M	— (loss-making)	— (loss-making)	+46.86% (above 0%: growing)	n/m	+58.67% (above 0%: growing)	12.39%	(1.47%)	Compare
NRC National Research Corporation	$466.9M	80.6×	4.9×	+3.98% (above 0%: growing)	n/m	+101.49% (above 0%: growing)	61.67%	(9.15%)	Compare
Median of peers	$637.5M	80.6×	34.4×	+14.04%	—	+52.19%	64.98%	(6.30%)

All 51 Health Information Services stocks →

Phreesia, Inc. (PHR) key facts

Strength: Phreesia, Inc.’s revenue for fiscal 2026 (year ended January 2026) was $480.6 million, up 14.5% from fiscal 2025.
Phreesia, Inc. (PHR) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, PHR traded at $10.94, a market capitalization of $685.3 million.
Return on equity was 0.77% and debt-to-equity 0.41.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 0.65 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.